-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6, Deqi Pharmaceuticals announced that the National Medical Products Administration (NMPA) has approved the application of ATG-019 to carry out a phase I clinical trial, aiming to evaluate ATG-019 (single agent or combined with niacinER) in advanced solid tumors or advanced solid tumors in China.
Safety and tolerability in patients with non-Hodgkin's lymphoma.
It is understood that ATG-019 is an oral bioavailable PAK4 / NAMPT dual target inhibitor, which can exert anti-tumor effects through energy consumption, DNA repair inhibition, cell cycle arrest and cell proliferation inhibition, and ultimately lead to cell metabolism.
, Has anti-tumor activity on blood and solid tumor cells dependent on PAK4 and NAMPT signaling pathways.
Studies have found that in murine tumor models, the anti-tumor effect of ATG-019 combined with anti-PD-1 therapy is better than that of anti-PD-1 monotherapy, indicating that this combination therapy has the potential to treat tumors that are resistant to PD-1 dialysis patient.
Based on the experimental results of the previous anti-tumor animal model, ATG-019 has launched a phase I clinical trial (TEACH) of ATG-019 in the treatment of advanced solid tumors and non-Hodgkin’s lymphoma in Taiwan, China.
Phase I clinical trials in patients with advanced solid tumors and non-Hodgkin's lymphoma, and plans to further explore the combination of ATG-019 through clinical studies.
It is worth mentioning that, as the first p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT) oral inhibitor of its kind, ATG-019 has been used in multiple Asia-Pacific markets including Greater China, South Korea, Australia, New Zealand and ASEAN countries have obtained exclusive development and commercialization rights.
The clinical trial application of ATG-019 has been approved by the NMPA, which fully demonstrates the potential of the drug to prevent and treat Chinese patients.
In the future, I look forward to the launch of the first clinical trial of ATG-019 in mainland China, which will bring a new treatment option for patients with advanced solid tumors and non-Hodgkin's lymphoma.
End reference materials: [1] Deqi Pharmaceutical WeChat public account selected onlookers to exercise in the past is really important! Cell sub-news reveal: Skeletal muscle can delay brain and retina aging in a specific way.
Hot article April 2 | World Autism Day, the children who guard the stars together | An overview of the performance of 26 unprofitable biomedical companies in Hong Kong stocks in 2020 Is it necessary to exercise more than one? Cell Sub-Journal: Excessive exercise can cause damage to healthy people's mitochondrial function and impair glucose tolerance.
Science reveals: The intestine regulates nutritional metabolism according to eating conditions.
This cell is the key "modulator".
Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy life| Pharmaceutical company news| Drug inventory| Pharmaceutical Technology | Basic Research on Drug Side Effects/Translational Medicine Leukemia | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbiological Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-nano| 3D printing| Genetic testing| Single-cell sequencing| Gene editing| Assisted reproduction| Artificial intelligence| Precision medicine policy anticancer drugs| 4+7 volume procurement| Consumables| Filing system| Registrant system| Healthy China| New edition Essential medicine catalog| AI medical equipment| Telemedicine| Equity non-equity market/capital IPO| Financing| Cooperation| Funds| Hong Kong Stock Exchange| Science and Technology Innovation Board| Growth Enterprise Market| R&D Investment| Acquisitions| Market & Consumption
Safety and tolerability in patients with non-Hodgkin's lymphoma.
It is understood that ATG-019 is an oral bioavailable PAK4 / NAMPT dual target inhibitor, which can exert anti-tumor effects through energy consumption, DNA repair inhibition, cell cycle arrest and cell proliferation inhibition, and ultimately lead to cell metabolism.
, Has anti-tumor activity on blood and solid tumor cells dependent on PAK4 and NAMPT signaling pathways.
Studies have found that in murine tumor models, the anti-tumor effect of ATG-019 combined with anti-PD-1 therapy is better than that of anti-PD-1 monotherapy, indicating that this combination therapy has the potential to treat tumors that are resistant to PD-1 dialysis patient.
Based on the experimental results of the previous anti-tumor animal model, ATG-019 has launched a phase I clinical trial (TEACH) of ATG-019 in the treatment of advanced solid tumors and non-Hodgkin’s lymphoma in Taiwan, China.
Phase I clinical trials in patients with advanced solid tumors and non-Hodgkin's lymphoma, and plans to further explore the combination of ATG-019 through clinical studies.
It is worth mentioning that, as the first p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT) oral inhibitor of its kind, ATG-019 has been used in multiple Asia-Pacific markets including Greater China, South Korea, Australia, New Zealand and ASEAN countries have obtained exclusive development and commercialization rights.
The clinical trial application of ATG-019 has been approved by the NMPA, which fully demonstrates the potential of the drug to prevent and treat Chinese patients.
In the future, I look forward to the launch of the first clinical trial of ATG-019 in mainland China, which will bring a new treatment option for patients with advanced solid tumors and non-Hodgkin's lymphoma.
End reference materials: [1] Deqi Pharmaceutical WeChat public account selected onlookers to exercise in the past is really important! Cell sub-news reveal: Skeletal muscle can delay brain and retina aging in a specific way.
Hot article April 2 | World Autism Day, the children who guard the stars together | An overview of the performance of 26 unprofitable biomedical companies in Hong Kong stocks in 2020 Is it necessary to exercise more than one? Cell Sub-Journal: Excessive exercise can cause damage to healthy people's mitochondrial function and impair glucose tolerance.
Science reveals: The intestine regulates nutritional metabolism according to eating conditions.
This cell is the key "modulator".
Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy life| Pharmaceutical company news| Drug inventory| Pharmaceutical Technology | Basic Research on Drug Side Effects/Translational Medicine Leukemia | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbiological Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-nano| 3D printing| Genetic testing| Single-cell sequencing| Gene editing| Assisted reproduction| Artificial intelligence| Precision medicine policy anticancer drugs| 4+7 volume procurement| Consumables| Filing system| Registrant system| Healthy China| New edition Essential medicine catalog| AI medical equipment| Telemedicine| Equity non-equity market/capital IPO| Financing| Cooperation| Funds| Hong Kong Stock Exchange| Science and Technology Innovation Board| Growth Enterprise Market| R&D Investment| Acquisitions| Market & Consumption
